Synplogen Co., a synthetic biology startup emerging from Kobe University's Graduate School of Science, Technology, and Innovation, is set to collaborate with Ginkgo Bioworks (NYSE: DNA), a company at the forefront of developing a platform for cell programming and biosecurity. The two entities have formally entered into a non-binding Memorandum of Understanding ("MOU") with the shared objective of accelerating the global advancement of DNA manufacturing and gene therapy platform services within Japan.
The collaborative efforts between Ginkgo and Synplogen will involve exploring potential global business partnerships in the field of DNA manufacturing. Synplogen's OGAB™ DNA synthesis services, known for their ability to synthesize DNA of various lengths, up to 100 kbp, and handle complex DNA synthesis, including high/low guanine-cytosine content and repeat sequences, will play a significant role in this venture.
Moreover, the partnership aims to extend the accessibility of Ginkgo's gene therapy services in the Japanese market. Synplogen intends to support this expansion by providing business development and marketing assistance, fostering connections between Ginkgo's services and Japanese biotechnology and pharmaceutical companies. Ginkgo, equipped with its end-to-end AAV gene therapy development platform and unique expertise in high-throughput design and synthesis optimization, seeks to drive progress in the Japanese bioeconomy.
Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed excitement about the collaboration, highlighting Japan's historical leadership in bioeconomy innovations. He emphasized the partnership with Synplogen as a means to grow their cell and gene therapy service offerings in Japan while contributing to the dynamic and inventive Japanese bioeconomy.
Kazuhiko Yamamoto, Representative Director and CEO of Synplogen, conveyed his appreciation for the recognition of their DNA synthesis technology by Ginkgo Bioworks, a global leader in biofoundry. He looks forward to the positive impact of Ginkgo's contributions in driving growth within Japan's bioeconomy, aligning seamlessly with Synplogen's commitment to advancing innovative solutions in the Japanese biotech sector.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!